Skip to main content
  Cornell University

MAE Publications and Papers

Sibley School of Mechanical and Aerospace Engineering

New article: Riboflavin Crosslinked High-density Collagen Gel for the Repair of Annular Defects in Intervertebral Discs: An in vivo study

Article:  Grunert, P; Borde, BH; Towne, SB; Moriguchi, Y; Hudson, KD; Bonassar, LJ; Hartl, R; (2015)  “Riboflavin Crosslinked High-density Collagen Gel for the Repair of Annular Defects in Intervertebral Discs:  An in vivo study”, ACTA Biomaterialia, 26: 215-224


Abstract:  Open annular defects compromise the ability of the annulus fibrosus to contain nuclear tissue in the disc space, and therefore lead to disc herniation with subsequent degenerative changes to the entire intervertebral disc. This study reports the use of riboflavin crosslinked high-density collagen gel for the repair of annular defects in a needle-punctured rat-tail model. High-density collagen has increased stiffness and greater hydraulic permeability than conventional low-density gels; riboflavin crosslinking further increases these properties. This study found that treating annular defects with crosslinked high-density collagen inhibited the progression of disc degeneration over 18 weeks compared to untreated control discs.

Histological sections of FITC-labeled collagen gel revealed an early tight attachment to host annular tissue. The gel was subsequently infiltrated by host fibroblasts which remodeled it into a fibrous cap that bridged the outer disrupted annular fibers and partially repaired the defect. This repair tissue enhanced retention of nucleus pulposus tissue, maintained physiological disc hydration, and preserved hydraulic permeability, according to MRI, histological, and mechanical assessments. Degenerative changes were partially reversed in treated discs, as indicated by an increase in nucleus pulposus size and hydration between weeks 5 and 18. The collagen gel appeared to work as an instant sealant and by enhancing the intrinsic healing capabilities of the host tissue. (C) 2015 Published by Elsevier Ltd. on behalf of Acta Materialia Inc.

Funding Acknowledgement:  Synthes; BrainLab; Nuvasive

Funding Text:  Lawrence J. Bonassar PhD: Equity holder for 3D BioCorp, Roger Hartl MD: Speaking fees/Royalties from Synthes, BrainLab, Nuvasive. All other authors have nothing to disclose.

Skip to toolbar